Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of NL-101 in relapsed or refractory follicular lymphoma or mantle cell lymphoma
CTR20211333Phase 2Active
- Sponsor
- Hangzhou Minsheng Pharmaceutical Group
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinostamustine in follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by Hangzhou Minsheng Pharmaceutical Group. Started Jun 2021; status: active.
02
Drugs
tinostamustine
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20211333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211333.